Published on 20 Jan 2022 on Zacks via Yahoo Finance
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
CytomX Therapeutics, Inc. CTMX announced that the FDA has approved its investigational new drug application for commencing a clinical study that will evaluate CX-904 for the treatment of advanced solid tumors.
CytomX is co-developing CX-904, a conditionally activated T-cell-engaging bispecific antibody, against the epidermal growth factor receptor (“EGFR”) on tumor cells and CD3 receptor on T cell, in partnership with biotech giant Amgen Inc. AMGN.
In 2017, CytomX entered into a collaboration and license agreement with Amgen. Back then, the company received an upfront payment of $40 million from Amgen.